Goodwin Procter advised Grey Wolf Therapeutics on the deal, while DLA Piper advised Pfizer Ventures and Earlybird Venture Capital. Grey Wolf Therapeutics announced its $49 million Series B...
This content is for Standard 1 Year members only. LoginJoin Now